ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
This workbook pulls in results from New Seed's three cost-effectiveness models: S-curve 1 (Central America), S-curve 2 (Africa), and S-curve 3 (gene editing).
2
The table below describes what is contained in each tab of this summary workbook.
3
4
TabContents
5
Portfolio summarySummarizes the cost-effectiveness of the full portfolio of New Seed's current and future work. Reduced childhood stunting is valued through associated reductions in childhood mortality as well as long-term cognitive benefits.
6
Alternative portfolio summarySummarizes the cost-effectiveness of the full portfolio of New Seed's current and future work. Reduced childhood stunting is valued based on DALYs per case of stunting averted, as developed by Kasey Markel.
7
Core Central America summarySummarizes the cost-effectiveness of the full portfolio of New Seed's current work in Central America, with costs limited to core Central America operating costs. Reduced childhood stunting is valued through associated reductions in childhood mortality as well as long-term cognitive benefits.
8
Alternative core Central America summarySummarizes the cost-effectiveness of the full portfolio of New Seed's current work in Central America, with costs limited to core Central America operating costs. Reduced childhood stunting is valued Reduced childhood stunting is valued based on DALYs per case of stunting averted, as developed by Kasey Markel.
9
Links to S-curvesProvides links to the detailed, country-specific cost-effectiveness models that underlie each S-curve
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100